$GILD Surges 5% on HIV Pipeline Optimism, Eyes $144 Breakout

$Gilead Sciences(GILD)$

$Gilead Sciences, Inc.(GILD) Surges +5.21%: HIV Pipeline Strength Drives Rebound Towards Key Resistance 🚀

Latest Close Data 📊

Closed at $136.36 on 2026-07-08, a strong gain of +5.21% (+$6.75). The stock is now trading 13.3% below its 52-week high of $157.29.

Core Market Drivers 💡

1. The rally was directly fueled by HSBC upgrading GILD from "Hold" to "Buy" on July 6th, raising its price target to $155.

2. This analyst confidence is underpinned by solid progress in Gilead's HIV pipeline, including recent positive Phase III data for the weekly oral regimen Islatravir/Lenacapavir.

Technical Analysis 📈

• Volume was elevated at 9.18M shares (volume ratio: 1.15), confirming the bullish move.

• The 6-day RSI surged to 77.9, indicating strong momentum but nearing overbought territory.

• The MACD shows a bullish crossover, with DIF turning positive and the histogram expanding to 2.51, signaling strengthening upward momentum.

Key Price Levels 🎯

• Immediate Pivot: $136.60 (Today's High)

• Strong Resistance: $144.21

• Primary Support: $127.81

Valuation Perspective 💎 Trades at a P/E (TTM) of 18.55x, which is reasonable for a large-cap biopharma. Its P/S ratio of 5.69x reflects its established revenue base.

Analyst Targets 🎯 Sentiment is bullish. 27 analysts have an average price target of $158.94, with a high of $180. The consensus rating is "Buy," supported by 8 Strong Buy and 18 Buy recommendations.

Weekly Outlook 🔮 The stock is testing immediate resistance. Expect consolidation between $136-$144 in the coming week. A decisive break above $144.21 could open the path toward the $150-$155 zone. A failure to hold $136 may lead to a pullback toward the $128 support.

Risk Disclaimer ⚠️ This analysis is for informational purposes only and not investment advice. All trading involves risk. Past performance does not guarantee future results. Please conduct your own research.